Breast cancer metastatic breast cancer.
Conditions
Interventions
Local hospital procedures for dosage and administration of trastuzumab will be
followed. Dose modifications because of developed toxicities are left to the
discretion of the responsible oncologist.
Sponsors
Antoni van Leeuwenhoek Ziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients who will be treated with trastuzumab in their best interest as single agent or in combination with chemo- or hormonal therapy (15 patients), or who are about to discontinue treatment with trastuzumab (15 patients for elimination curve), Age >18 years, written informed consent prior to participation in the trial, Able and willing to undergo blood and urine sampling.
Exclusion criteria
Exclusion criteria: The common exclusion criteria regarding trastuzumab treatment will be followed, and left to the discretion of the treating physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint of this study is to obtain peptide phosphorylation profiles of patients treated with trastuzumab. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints of this study are to correlate the generated phosphorylation profiles as well as metabolic and proteomic changes following trastuzumab treatment to trastuzumab pharmacokinetics . | — |
Countries
Netherlands
Outcome results
None listed